In AML, we previously demonstrated that binding of c-Myc to Rad51 and CHEK1 promoters is significantly decreased by selinexor treatment, therefore proposing at least one direct mechanism of action by which selinexor can directly reduce expression of DDR genes [30]. Here, CHEK1 is linked to acute myeloid leukemia.